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Hepatitis E virus (HEV) causes acute hepatitis in humans, predomi-
nantly by contamination of food and water, and is characterized by
jaundice and flu-like aches and pains. To date, no vaccines are
commercially available to prevent the disease caused by HEV.
Previously,we showed that amonoclonal antibody, 8C11, specifically
recognizes a neutralizing conformational epitope onHEV genotype I.
The antibody 8C11 blocks the virus-like particle from binding to and
penetrating the host cell. Here, we report the complex crystal
structure of 8C11 Fab with HEV E2s(I) domain at 1.9 Å resolution.
The 8C11 epitopes on E2s(I) were identified at Asp496-Thr499, Val510-
Leu514, andAsn573-Arg578.Mutations and cell-model assays identified
Arg512 as the most crucial residue for 8C11 interaction with and neu-
tralization of HEV. Interestingly, 8C11 specifically neutralizes HEV
genotype I, but not the other genotypes. Because HEV type I and
IV are the most abundant genotypes, to understand this specificity
further we determined the structure of E2s(IV) at 1.79 Å resolution
and an E2s(IV) complex with 8C11 model was generated. The com-
parison between the 8C11 complexeswith type I and IV revealed the
key residues that distinguish these two genotypes. Of particular in-
terest, the residue at amino acid position 497 at the 8C11 epitope
region of E2s is distinct among these two genotypes. Swapping this
residue from one genotype to another inversed the 8C11 reactivity,
demonstrating the essential role played by amino acid 497 in the
genotype recognition. These studies may lead to the development
of antibody-based drugs for the specific treatment against HEV.
Infectious viral hepatitis is a major threat to public health.Hepatitis E is one of the most important pathogenic viruses
capable of infecting humans, with the highest incidence in patients
aged 15 to 40 y (1). Hepatitis E infection causes severe liver in-
flammation, characterized by jaundice, fever, liver enlargement,
and abdominal pain in humans and nonhuman primates (2).
Hepatitis E virus (HEV) is prevalent in most tropical developing
countries and is responsible for high rates of mortality in pregnant
women by the development of fulminant liver disease (3).
The HEV genome is a positive-stranded RNA that encodes
different proteins. One of these genes (ORF2) encodes a single
structural protein of 660 aa, which form the capsid through its
homodimeric subunits (domain E2 amino acids 394–606; domain
E2s amino acids 455–602) (4, 5). These dimers are shown to
protrude from the viral surface and believed to interact with host
cells to initiate infection (5, 6). We recently elucidated the ter-
tiary structure of E2s genotype I, the protruding domain of HEV,
and through functional studies we have illustrated the tight
homodimeric nature of E2s and identified that dimerization is
essential for both HEV–host interactions and disease progres-
sion. Moreover, we mapped the neutralizing antibody recogni-
tion site of HEV on the E2s(I) domain (5).
In parallel, two crystal structures of HEV-like particles
(ORF2, amino acids 112–608) were reported both at 3.5 Å for
genotype III (6) and genotype IV (7). In these structural studies,
three domains were defined: the shell domain (amino acids 129–
319), which adopts a jelly-roll fold, and the middle (amino acids
320–455), and protrusion domains (amino acids 456–606), which
both adopt a β-barrel fold. More recently, cryo-electron mi-
croscopy and image reconstructions revealed the binding of anti-
HEV monoclonal antibodies to the protruding domain of the
capsid protein at the lateral side of the spikes (8).
Several monoclonal antibodies against the HEV E2 domain
have been raised to bind to the live HEV and affect immune
capture of this virus (9). At least two of these antibodies, 8C11
and 8H3, can neutralize the infectivity of HEV. Moreover, these
antibodies can act synergistically in their neutralization (9),
suggesting that there are two interaction- and conformation-
dependent neutralization sites on the HEV particle, which may
cooperate in the adsorption and penetration of the HEV virus.
To better understand the structural basis for the neutralization
mechanism, here we report the crystal structure of HEV pro-
truding domain E2s (genotype I) in complex with the neutrali-
zation mAb 8C11 Fab, refined up to 1.9 Å. Structure-based site-
directed mutagenesis was performed to identify the key residues
involved in the interaction between E2s and mAb 8C11. Because
8C11 specifically recognizes the HEV genotype I and weakly
binds to genotype IV, we also determined the crystal structure of
E2s(IV) at 1.79 Å and generated an 8C11 complex model, and
mapped the fine structural variations between the E2s(I) and E2s
(IV) genotypes. Functional studies on several residues from both
genotypes (I and IV) identified the key determinants that dif-
ferentiate the specificity of binding. Studies on E2s-Fab complex
have provided critical information on their binding specificity
toward recognizing their neutralization antibody. The 8C11
epitope identified here may help in the development of antibody-
based therapies for the treatment for HEV.
Results and Discussion
Overall Structure. The structure of E2s(I) in complex with the
8C11 Fab fragment was solved at 1.9 Å resolution (Table S1). In
the asymmetric unit, one dimer of E2s(I) binds with two 8C11
Fab (Fig. 1) and this observation is consistent with the analytical
ultra-centrifugation (AUC) results (Fig. S1). In E2s, the Fab
interaction surface is located on the opposite side of the di-
merization interface surface. Similar to the apo form, E2s(I) in
the complex adopts the β-barrel fold and maintains a tight di-
meric architecture. The 8C11-bound E2s(I) was able to be su-
perimposed onto the unbound E2s(I) structure with an rmsd of
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0.7 Å for all of the 144 Cα atoms (amino acids 459–602) by the
DaliLite server (11). This finding indicates that there is no
conformational change to the protruding domain E2s(I) of HEV
upon binding with 8C11 Fab, and suggests that the 8C11 epitope
on the E2s(I) domain has a relatively stable conformation.
In the complex, the 8C11 Fab molecule has a well-defined elec-
tron density map, except where it is disordered in the loop region in
the heavy chain between SerH139 and ThrH144, located away from
theE2s interaction surface (the superscripted “H” denotes residues
within the heavy chain; a superscripted “L” will denote residues
within the light chain). This region of Fab is often found disordered
in other Fab structures (11). The 8C11 Fab has a canonical sand-
wich Ig fold (12): the heavy chain folds intoVHandCHdomains and
the light chain folded with VL and CL domains (Fig. 1A).
Interactions Between E2s(I) and 8C11 Fab. The interactions between
E2s(I) and 8C11 Fab buries a total of 1763 Å2 of the surface area
as calculated by PISA (13). Approximately 66% (or 876 Å2) of
the total buried surface area of E2s(I) is because of the binding
of heavy chain.
A hydrophobic cluster at the binding interface consists of the side
chains from Thr476, Thr499, and Val510 of E2s(I) with TrpL92 and
TyrL30 of 8C11 Fab. The hydrophobic loop region of heavy chain
H103VITTH106 is in close contact with E2s(I) (Fig. 1 B and E).
There are eight hydrogen-bonding contacts (< 3.2 Å) observed
between E2s(I) and 8C11 Fab. In addition, this complex is stabi-
lized by numerous van der Waals interactions. The specificity of
8C11 Fab to E2s(I) is dictated by three major interactions at
Asp496-Thr499, Val510-Leu514, and Asn573-Arg578 of E2s(I) (Fig.
1D). These observations are consistent with our previous E2s(I)
mutational studies to disrupt antibody binding to this epitope (5).
We showed that the mutants Glu479Ala, Tyr485Ala, and
Lys534Ala significantly reduced the binding of 8C11 with E2s(I).
Moreover, mutant Asp496Ala completely abrogated the interaction
with 8C11. In this complex structure, hydrogen-bonding contacts
were established between the side chains of all of these residues
and the residues of 8C11 Fab. Notably, Arg512 of E2s(I) is involved
in several interactions with 8C11: Arg512 interacted not only with
8C11 heavy chain (ThrH105, ThrH106, GlyH107, andTyrH109) but also
with the light chain (AsnL32 and PheL91) (Fig. 1 D and E).
Structure-Based Mutational Analysis of the Neutralizing Sites. In the
E2s(I):8C11 Fab complex structure, several amino acids located on
the interface were observed to interact with 8C11 Fab through their
side chains, including Glu479, Ser497, Arg512, His577, Arg578, and
Lys534 ofE2s(I). Structure-based functional studies were performed
on the E2 constructs to determine the relevant importance of these
interactions (Fig. 2). Systematically, a series of mutated E2 con-
structs were generated by replacing these interacting amino acids
with alanine. Each construct existed mainly as a dimer in SDS/
PAGE (Fig. 2A) and this is consistent with the AUC experiments
thatE2andeachmutant existedasdimers (∼2.6S) in solution (Fig. 2
C and D and Fig. S2). Only Arg512Ala abolished the interaction
with 8C11 in Western blotting and in AUC experiments (Fig. 2).
To further determine the potential role of Arg512, five E2
mutants were generated, replacing Arg with Glu, Leu, Lys, His,
or Tyr. Similar to Arg512Ala, all of these mutants failed to in-
teract with 8C11 mAb observed in Western blot experiments
(Fig. 2B), although they all existed as dimers in SDS/PAGE (Fig.
2B) and in AUC experiments (∼2.7 S) (Fig. S3). However, the
Fig. 1. Structure of E2s(I) in complex with the neutralizing antibody 8C11 Fab illustrates the neutralizing epitope. (A) Ribbon diagram of the E2s(I):8C11 Fab
complex structure. E2s(I), 8C11 Fab heavy chain, and 8C11 Fab light chain are depicted in green (light and dark green to both monomers), purple and yellow,
respectively. VH and CH domains of the heavy chain as well as VL and CL domains of the light chain are labeled. (B) A close-up view of the interaction of 8C11with
E2s(I) shownas surface representation. The interacting loops 1 (TyrL30-LeuL33), 2 (PheL91-AsnL94), 3 (SerH102-TyrH109), and 4 (TrpH54-ArgH60) from8C11were labeled
and highlighted in green, blue, pink, and black, respectively. (C) Surface representations of E2s(I):8C11 complex structure. (D) Surface representations of E2s(I)
highlighted the interacting epitope residues in a dark shade. The epitope residues are shown in purple and yellow corresponding to their interactions to 8C11
heavy chainand light chain, respectively.Arg512 is labeled in redas it interactswithboth chains. (E)Depicts theelectrostatic potential surfaceof theepitopeon the
E2s(I) (red, negative; blue, positive; and gray, neutral) with the key residues for interaction from 8C11 loops 1, 2, 3, and 4 represented as sticks. Thisfigure and the
following figures of this manuscript were prepared using the program PyMOL (27).











AUC analysis shows that only Arg512Glu mutant abrogated the
immune complex formation (Fig. 2E and Fig. S3). These results
suggest that electrostatic interactions play a key role in mAb
binding and clearly demonstrate that Arg512 plays a critical role
in 8C11 antibody binding. The side-chain guanidine group of
Arg512 forms hydrogen-bonding contacts (<3.0 Å) with the car-
bonyl oxygen (O) of PheL91 and the side chain oxygen (OD1) of
AsnL32 from the light chain of 8C11.
Cell-Binding Analysis of HEV Virus-Like Particles and Its Mutants. A
recombinant mutant of HEV E2 (ORF2 amino acids 368-606),
p239, which forms virus-like particles (VLPs). This particle could
specifically absorb and penetrate susceptible host cells like live
viruses (14). Previously, we have shown that the penetration and
entry of p239 to vulnerable Huh7 cells can be blocked by either
of two monoclonal antibodies: (i) 8C11, which recognizes a neu-
tralizing conformational epitope; and (ii) 12A10, which recog-
nizes a linear epitope located at amino acids 423–438 of E2.
However, the removal of either epitope cannot completely abolish
the binding capacity of p239 with Fab (15).
Based on the E2s(I):8C11 complex structure, alanine scanning
mutagenesis on the interface amino acids were performed to
generate constructs of p239, a truncated structural protein of
HEV (VLP). All mutants maintained particulate form, compa-
rable with the prototype p239. The cell-model assay showed that
a tetra mutant, p239-Δ8C11A (Ser497Ala, Arg512Ala, His512Ala,
and Arg578Ala) showed a reduced capacity to penetrate the host
cell (Fig. 3A). However, mutating other amino acids of the 8C11
epitope on E2s had no effect (Fig. S4).
Next, we tested the penetration and entry of p239 to vulner-
able cells when both 8C11 and 12A10 epitope sites were mu-
tated. The p239 linear 12A10 epitope was substituted with
tandem histidines (named as Hp239) and observed to maintain
comparable entry capacity as the control p239. However, further
mutation of Arg512Ala within the 8C11 binding site on Hp239
completely abrogated p239–host cell interaction (Fig. 3B).
Therefore, the conformational 8C11 epitope and the linear
12A10 epitope are the only virus–host interaction sites; more
importantly, Arg512, which is located on the E2 domain, is the
most crucial residue for neutralizing HEV. This finding is further
supported by its strategic position of Arg512 and the interactions
with 8C11, as revealed by the complex crystal structure.
Structure of E2s(IV) and Genotype-Specific HEV Neutralization. HEV
is the only member of the genus Hepevirus in the family Hepe-
viridae (16). In this family, four mammalian genotypes have been
identified, but with a single serotype (17). The HEV in genotypes
I and II are found in humans, but those in genotypes III and IV
infect both humans and swine (16).
After identifying the 8C11 epitopes on E2s(I), we sought to
investigate why HEV genotype IV is not neutralized by 8C11 and
to identify the key determinants, which discriminate these two
most abundant genotypes. Because the E2s domain is the pro-
truding region of HEV, which is essential for host recognition, the
structural comparison between E2s types I and IV may provide the
clue for their specificities toward host recognition (Fig. 4).
As a first step, the crystal structure of type IV E2s was solved at
1.79 Å resolution (Table S1). The asymmetric unit consists of an
E2s(IV) dimer (Fig. 4B). The structural comparisons of the pro-
truding domain of HEV from three known crystal structures of
different genotypes were performed. Two high-resolution struc-
tures of the E2s domain from genotypes I and IV of this study and
the 3.5 Å resolution structure of VLP from the genotype III (6)
were taken for this comparison. In all three cases, a similar
structure is adopted, which is consistent with there being a single
serotype for four HEV genotypes. The tight dimeric architecture
of E2s(I) superimpose well with the dimeric E2s(IV) and E2s(III)
(Fig. 4C). The rmsd for pairwise comparison are 0.7 Å (between I
and IV), 1.3 Å (between I and III), and 1.4 Å (between III and IV)
for all Cα atoms of the E2s domain. This finding suggests that in
Fig. 2. Mutational studies on the E2s(I):8C11 in-
teraction interface. (A and B) The mutants and
wild-type E2 were subjected to nonreducing SDS/
PAGE andWestern blotting with the neutralizing
mAb 8C11 to study the effects of these mutations
on E2s(I):8C11 interaction. The lanes markedwith
H indicate heated samples in the reduced condi-
tion (i.e., these samples were heated up to 100 °C
for 3 min) and the lanes marked with N indicate
samples in the nonreducing condition (i.e., these
samples with 0.1% SDS, no β-mercaptoethanol,
and were not heated). (+) Denotes dimerization
or reactivity with 8C11, (−) denotes monomer or
loss of the respective property. (C–E) Sedimenta-
tionvelocity (SV)wasused todetect themAb8C11
binding of E2s(I) (C), and the mutants Arg512Ala
(D) and Arg512Glu (E). The c(s) profile of E2, its
mutants, or mAb 8C11 alone was denoted as a
dashed curve. Theprofile of the antigen-antibody
mixtures was drawn in a solid line. Molar ratio of
E2 or its mutant versus mAb 8C11 was 5:1, mean-
ing the antigen was in surplus.
Fig. 3. Binding of VLP p239 and its mutants to Huh7 cells. (A) Binding of
p239 and its tetra mutant p239-Δ8C11A (Ser497Ala, Arg512Ala, His512Ala,
and Arg578Ala) to Huh7 cells were detected by Western blotting. With the
intrinsic β-tubulin controlled in same level, p239-Δ8C11A decreased in
binding capacity with respect with protype p239. (−) Denotes the absence of
the blocking mAb (8G12), (+) denotes the presence of this blocking mAb. (B)
Hp239 mutant maintains the binding capacity compared with the prototype
p239. The Arg512Ala mutation on Hp239 (Hp239-Arg512Ala) construct
completely abrogates cell binding.
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all HEV genotypes the dimerization of the protruding domain of
the capsid is essential for its interactions with the host.
Type Diversity Between Genotype I and IV on the 8C11 Binding Site.
To understand the specificity of mAb 8C11 toward E2s(I), the
complex model of E2s:8C11 for genotype IV was generated by
superimposing the E2s(IV) structure with the E2s(I) of the
E2s:8C11 complex using the Dalilite server (10). The comparison
between type I complex crystal structure and type IV complex
model revealed the type diversity between these two genotypes
in 8C11 recognition (Fig. 5). In the 8C11 epitope regions, two
amino acid differences exist: genotype I contains Ser497(I) and
Ala575(I), whereas genotype IV contains Thr497(IV) and Pro575(IV)
[superscript “I” or “IV” denotes the residue in E2s(I) or E2s(IV),
respectively] (Fig. 4A and 5C). In the E2s(I):8C11 complex,
Ser497(I) makes a hydrogen-bonding contact with GlyL93 of 8C11
Fab, as well as a hydrogen-bonding contact within E2s withArg512(I)
(Fig. 5B). However, the superimposed E2s(IV):8C11 complex
model reveals that the key interactions mediated throughArg512(IV)
were completely disrupted (Fig. 5D): the Arg512(IV) side chain no
longer interacted with Thr497(IV), and moved away from 8C11 so
that it also did not interact with AsnL32 of 8C11. Notably, in this
model the Cβ group of Thr
497(IV) is in a position to have steric
clashes with TrpL92 of 8C11, indicating that it is not an optimal
residue for this position to interact with 8C11. These observations
led to the hypothesis that the residue in the amino acid 497 position
is essential to differentiate between the genotypes I and IV.
Fig. 4. Structural comparison of E2s
domains across the different genotypes. (A)
Structure-based sequence alignment be-
tween E2s genotype I, III, and IV was per-
formed using the program COOT (23). The
secondary structural elements for E2s(I) was
shown and the conserved residues are high-
lighted in red boxes outlined in blue. This
figure was created by using the program
ESPript (28). (B) Ribbon diagram of dimeric
E2s(IV) is shown in red. (C) Cα superposition
of dimeric E2s of genotype I (green), geno-
type III (cyan), and genotype IV (red).
Fig. 5. Genotype specificity determinants for virus
neutralization. (A) Three major 8C11 epitope clus-
ters on E2s(I) are shown in ball and stick model and
colored green. The 8C11 Fab was shown as surface
representation. (B) A close-up view of the side chain
of the key residue Arg512 interacts with TyrH109 and
AsnL32 of 8C11. Meanwhile, Arg512 forms a hydro-
gen bonding contact with Ser497, which in turn
interacts with GlyL93 of 8C11. The 2Fo-Fc map is
shown and contoured at a level of 1.0σ. The hy-
drogen bonding contact was shown in dashed line.
(C and D) Overlay of crystal structures of E2s(I) and
E2s(IV) in the region of 8C11 epitope, showing the
conservation and differences between these two
genotypes.











To validate this hypothesis, two constructs were generated by
swapping amino acid 497 on E2(I) and E2(IV): E2(I)-Ser497Thr
and E2(IV)-Thr497Ser. These two mutants existed as dimers in
SDS/PAGE, similar to their prototype E2(I) and E2(IV), re-
spectively (Fig. 6A). In the 8C11 Western blot analysis, E2(IV)-
Thr497Ser showed a significant increase in its reactivity, whereas
E2(I)-Ser497Thr showed a decrease in reactivity, compared with
their respective wild types (Fig. 6A). Moreover, the binding af-
finity determination (Biacore) showed that both E2(I) and E2
(IV) proteins with amino acid Ser497 have a 2-log higher affinity
than the proteins with aaThr497 (Table 1). These results suggest
that amino acid 497 plays a crucial role in 8C11 binding and
HEV neutralization. Mutating Ser497 in E2(I) with Glu, His, Leu,
Lys, or Tyr abrogated the reactivity with 8C11 observed in both
Western blot and in AUC experiments (Fig. 6B and Fig. S5).
Based on the genotype diversity of E2, we used ELISA ex-
periments to screen several genotype-specific mAbs that were
raised previously (9). Eight antibodies that are deemed as spe-
cific genotype I antibodies were identified, and demonstrated at
least a 10 times higher OD with genotype I antigens E2(I) than
E2(IV) (Table 2 and Table S2). We then used the two amino acid
497 mutants [E2(I)-Ser497Thr and E2(IV)-Thr497Ser] to per-
form the same ELISA analysis. As shown in Table 2, four of the
eight antibodies have at least a two times higher reactivity with
mutant E2(IV)-Thr497Ser compared with E2-Ser497Thr (8C11,
1A5, 8E10, and 12A7). In particular, 8C11 reacted at least three
times higher with E2 genotype I than genotype IV; however, the
reactivity of mutant E2(IV)-Thr497Ser was higher than mutant
E2(I)-Ser497Thr. It is important to note that only one residue
(amino acid 497) was mutated to that of a different genotype, the
reactivity of antibodies was inversed. These results demonstrate
that amino acid 497 plays a crucial role in the recognition of
genotype I and IV by these antibodies, including 8C11.
To visualize the binding mode of mAb 8C11 with HEV capsid,
a model was generated by superimposing the E2s(I):8C11 com-
plex onto the known models of HEV VLP (6, 7). The light chain
of the Fab showed a few clashes with the middle domain of the
VLP. One possibility is that the bound antibody with VLP might
undergo minor conformational changes to avoid these clashes.
Another possibility is the movement of the E2 domain through
the loop (Q449-R460), which is connecting the protruding E2
domain and the particle shell. It is worth mentioning here that
a rotation of the surface domain has been observed after the
neutralizing antibody binds to dengue virus (18) and HIV-1 (19).
Conclusions
HEV is responsible for severe liver disease in humans. Infection is
spreading by the fecal contamination of water supplies or food,
and it is most prevalent in developing countries and countries with
tropical climates. Recently, we have shown that HEV capsid
protein domain E2s (protruding domain) is a homodimer and the
dimerization of E2s is essential for HEV–host interactions (5).
The penetration and entry of HEV to vulnerable cells can be
blocked by the monoclonal antibody 8C11, which recognizes a
neutralizing conformational epitope. The present study sought to
elucidate the HEV:neutralizing antibody interaction to aid in the
development of effective therapeutic strategies against the virus.
A recombinant vaccine based on the E2s domain is in phase III
clinical trials (20); however, no vaccines are commercially avail-
able for the prevention of hepatitis E. Here, we report the crystal
structure of the neutralizing antibody 8C11 Fab in complex with
the protruding domain of HEV capsid, E2s. The antibody 8C11
recognizes three major regions of the HEV E2s domain: Asp496-
Thr499, Val510-Leu514, and Asn573-Arg578. Mutational analysis as
well as cell-model assays demonstrated that Arg512 on E2s is the
most crucial residue for 8C11 interaction and neutralization. The
antibody 8C11 is specifically neutralizing HEV genotype I but
weakly binds with other genotypes. It is worth mentioning here
that type I and IV are the most abundant genotypes whereas type
II is rarely observed. To understand how 8C11 discriminates dif-
ferent genotypes, we have determined the high-resolution struc-
ture of E2s from genotype IV at 1.79 Å resolution. Subsequently
we have constructed a model of E2s(IV):8C11 and compared it
with an E2s(I):8C11 complex crystal structure to identify the key
determinants, which discriminate these two genotypes. We iden-
tified different residues at the 8C11 epitope region, in position
amino acid 497, which plays a crucial role in the recognition of
genotypes I and IV. The results presented here will lead to the
designing of vaccines and specific novel inhibitors for HEV.
Materials and Methods
Cloning, Purification, Crystallization, and Structure Determination. The E2s, E2,
and p239 genes of HEV genotype I were cloned (14). The equivalent E2s and
E2 of HEV genotype IV were PCR-amplified from a swine HEV capsid protein
gene (GenBank no. GQ166778). All mutated constructs were generated with
site-directed PCR reactions. pTO-T7 expression plasmid and E.coli ER2566
strain were used for protein expression.
The HEV E2s(I) has been purified (5). The 8C11 Fab was obtained by papain
digestion and purified with DEAE-5PW (TOSOH). The E2s(I):8C11 (ratio of
1:1.5M) was kept at 37 °C for 2 h and purified by Superdex 200 (GE
Healthcare) and concentrated to ∼8 mg/mL. Crystals were grown by mixing
1 μL E2s(I):8C11 with 1 μL reservoir solution (0.1M Hepes pH 7.2, 0.4 M KSCN,
0.4 M NH4Cl, 18% PEG 3350, and 5% (wt/vol) n-Dodecyl-β-D-maltoside) using
hanging-drop vapor diffusion method at 21°C. Similarly, the HEV E2s(IV) was
purified, and crystals were grown from a reservoir solution consisting of
0.1 M Tris, pH 8.0 and 20% PEG 10 K. Thirty percent glycerol supplemented
with reservoir condition as cryo-protectant for both crystals and data col-
lected at 100 K. Data for crystals of E2s(I):8C11 was collected at beamline
BL13B1, NSRRC, Taiwan using an ADSC Quantum-315r CCD. E2(IV) data was
obtained using a CCD detector (Platinum135) mounted on a Bruker Micro-
star Ultra rotating anode generator. Datasets were processed by HKL2000
(21). The structures were solved by molecular replacement with PHASER (22).
The models were built using COOT (23), refined by CNS (24), and analyzed by
PROCHECK (25) (Table S1).
Fig. 6. The role of residue 497 in genotype-specific virus neutralization. (A)
Wild-typeE2(I) andE2(IV) aswell as twoaminoacid497mutants, E2(I)-Ser497Thr
and E2(IV)-Thr497Ser. (B) The single point mutations on Ser497 of E2(I) were
subjected tononreducing SDS/PAGEandWesternblottingwith theneutralizing
mAb 8C11 to study the role of Ser497 involved in genotype specific definition.






E2(I) 3.84 × 105 2.27 × 10−3 1.70 × 108 5.89
E2(I)-S497T 6.53 × 103 5.00 × 10−3 1.31 × 106 7.66 × 102
E2(IV) 3.42 × 103 2.21 × 10−3 1.55 × 106 6.46 × 102
E2(IV)-T497S 8.46 × 104 2.37 × 10−4 3.58 × 108 2.80
Ser497 for type I and Thr497 for type IV are strictly associated with the
binding strength of mAb 8C11. The details of the Biacore experiment are
described in SI Materials and Methods.
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Antibodies. The monoclonal antibodies were raised from E2(I), E2(IV), and
p239 antigens using standard murine mAb preparation protocol (9).
Analytical Ultra-Centrifugation. Sedimentation velocity (SV) was used to
monitor the binding of antigen and mAb in neutral solution (5). All samples
were diluted to ∼1.0 OD280nm in 1.2-cm light path with PBS (pH 7.4). The
rotor speed was set at 50,000 rpm for E2 and its mutants, 40,000 rpm
for mAb 8C11, and 30,000 rpm for the immune complex. The sedimenta-
tion coefficient was obtained with c(s) method (26) using the Sedfit
software kindly provided by P. Schuck (National Institutes of Health,
Bethesda, MD).
Binding Assay on Cell Model. Huh7 cells (human hapatoma cell line) were
incubated at 37 °C for 1 h with p239 or its mutants (20 μg) with or without
preincubating with neutralizing mAb 8G12 (200 μg). The harvested cells
were lysed in buffer (20 mM KOH-Hepes buffer, pH 8.0, 0.2 mM EDTA, 5%
glycerol, 250 mMNaCl, 0.5%Nonidet P-40, 0.25% sodium deoxycholate, 1 mM
DTT and protease inhibitors). 15B2 is the primary antibody for the Western
blot, which recognizes the linear epitope HEV ORF2 aa 403–418. Alexa Fluor
680-conjugated mouse anti–β-tubulin and rabbit anti–α-tubulin (Santa Cruz
Biotechnology) and Alexa Fluor 680-conjugated goat anti-mouse (Invi-
trogen) were then added and were examined by Odyssey (Li-COR).
ELISA Analysis. The antigen (100 ng/well) was coated in a 96-well microplate
and incubated with serial dilutions of each mAb at 37 °C for 1 h. Wells were
incubated with HRP-conjugated GAM for 30 min at 37 °C. Subsequently,
100 μL tetramethylbenzidine substrate was added and incubated for 10 min
at 37 °C. The reaction was stopped by adding 50 μL 2 M H2SO4, and the OD
was measured at 450 nm with a reference wavelength of 620 nm. The ab-
sorbance ratio of genotype I versus IV was calculated.
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Table 2. HEV E2 type I/IV with aa497 specificity recognition in a mAb pool
mAb
OD ratio in mAb dilution* E2(I)/E2(IV)
Type specificity†
OD ratio in mAb dilution* E2(IV)-T497S/E2
(I)-S497T
Amino acid 497 specificity†1:100 1:1 K 1:10 K 1:100 K 1:100 1:1 K 1:10 K 1:100 K
8C11 3 9 13 12 I 1/2 2 3 3 —
1A5 6 45 81 49 I 6 10 21 6 Ser
1E8 14 6 30 57 I 1/2 1 1 2 —
3B8 38 73 4 1 I 1 1 1 1 —
8E10 4 11 29 20 I 1/2 1 3 2 —
13D8 11 5 1 1/2 I 2 2 1 1 —
6F8 8 10 2 2 I 1/100 1/17 1/4 2 Thr
12A7 4 4 6 10 I 9 10 27 56 Ser
*The 2 mg/ml mAbs were diluted at 1:100, 1:1K, 1:10K, and 1:100K as primary antibody for ELISA.
†OD ratio for E2(I)/E2(IV) and E2(IV)-T497S/E2(I)-S497T was calculated for specificity interpretation of HEV type and amino acid 497. Cutoff values were set as
≥10 or ≤1/10 for more than one of four serial dilution OD ratios.
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